See every side of every news story
Get Started
SubscribeLogin
Everton
Donald Trump
Ukraine War
Volodymyr Zelenskyy
Viktor Orbán
Hamas
Basketball
Israel-Hamas Conflict
Manchester United
Elon Musk
Premier League
Soccer
Published • loading... • Updated

ImmunityBio gains FDA authorisation for BCG alternative

Summary by Pharmaceutical-technology.com
ImmunityBio has gained the FDA authorisation for an EAP to supply an alternative source of BCG for treating bladder cancer.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
Pharmaceutical CommercePharmaceutical Commerce

ImmunityBio to Supply Recombinant BCG to Alleviate Tice BCG Shortage

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

Read Full Article
pharmaceutical-technology.compharmaceutical-technology.com

ImmunityBio gains FDA authorisation for BCG alternative

ImmunityBio has gained the FDA authorisation for an EAP to supply an alternative source of BCG for treating bladder cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmaceutical-technology.com broke the news in on Thursday, February 20, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Merck

Merck

United States

United States

News
For You
Search
BlindspotLocal